---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Pathophysiology"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Pathophysiology. Topics: Tumor hyperinsulinism: insulin receptor over-activation as described by the manufacturer, Insulinoma: insulin secretion not suppressed during hypoglycemia, Insulinoma: somatic genetic and epigenetic changes, Aggressive (malignant) versus indolent insulinoma: pathologic and molecular features, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Tumor hyperinsulinism: insulin receptor over-activation as described by the manufacturer

> “Severe, persistent, life-threatening complication of over activation of the insulin receptor”
> “Excessive secretion of insulin”
> “Produce and secrete insulin-like paraneoplastic substances such as IGF-2 that over activate the insulin receptor”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.4-2"></a>

### Insulinoma: insulin secretion not suppressed during hypoglycemia

> “By definition, in endogenous hyperinsulinism, the insulin secretion does not decrease to very low levels when plasma glucose concentrations decrease to hypoglycemic levels”
> “Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.4-3"></a>

### Insulinoma: somatic genetic and epigenetic changes

> “Despite a low tumor mutational burden, insulinomas are enriched for genetic mutations and copy number variants in epigenetic modifiers”
> “The predominant recurring genetic variant in up to 30% of insulinomas is an activating T372R mutation in the Yin Yang 1 (YY1) gene, which is absent in nonfunctioning panNEN”
> “YY1 is a transcriptional activator of the insulin gene. MEN1 mutations appear to be less common in insulinomas than nonfunctioning panNEN, but insulinomas do display loss of heterozygosity of the MEN1 region at chromosome 11q13.1 in 30% of cases”
> “Insulinomas are also associated with aberrant methylation patterns, including of the insulin promoter, where noncanonical transcription factors drive insulin expression”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.4-4"></a>

### Aggressive (malignant) versus indolent insulinoma: pathologic and molecular features

> “Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype and chromosomal instability.”
> “Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells.”

Source: [Hackeng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36779771/)

<a id="topic-2.2.1.4-5"></a>

### Malignant versus benign insulinoma: hormone concentrations and tumor size in a single-center cohort

> “Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide. Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.4-6"></a>

### Non-islet cell tumor hypoglycemia: tumor IGF-2 release with suppressed insulin, IGF-1, and growth hormone

> “Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.”
> “Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH. Complicating the pathophysiology are the IGF binding proteins (IGFBPs) that can bind IGF-2 and IGF-1, modifying hormone metabolism and action.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.4-7"></a>

### Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability

> “Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.”
> “The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.”
> “This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.”
> “Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.”
> “The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

<a id="topic-2.2.1.4-8"></a>

### Non-islet cell tumor hypoglycemia: effects of IGF-2 on glucose uptake, hepatic glucose output, and glucagon

> “IGF-2 produced by tumor cells binds to IRs in skeletal muscle cells, leading to increased glucose uptake.”
> “In the liver, IGF-2 suppresses gluconeogenesis, glycogenolysis, ketogenesis, and the activity of glucose-6-phosphatase, thereby blocking hepatic glucose release.”
> “Additionally, IGF-2 binds to IGF-1 and IR receptors on pancreatic alpha cells, suppressing glucagon release and exacerbating hypoglycemia.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “IGF‐2 typically demonstrates weak affinity for insulin receptors under normal physiological conditions. However, abnormally elevated levels of IGF‐2 can result in sufficient stimulation of insulin receptors, potentially inducing a state of clinically significant hypoglycaemia.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.4-9"></a>

### Non-islet cell tumor hypoglycemia: hypoinsulinemia and large tumor size in a Japanese series

> “The diameters of the tumors were more than 10 cm in 70% of the patients. Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
